AngioDynamics has obtained an FDA green light for its NanoKnife prostate cancer ablation system, designed to precisely target ...

AngioDynamics, Inc. ANGO, yesterday, announced the receipt of the FDA’s 510(k) clearance for the NanoKnife System for ...

AngioDynamics received FDA 510(k) clearance for its NanoKnife system for prostate tissue ablation in intermediate-risk ...

AngioDynamics has won US Food and Drug Administration (FDA) clearance for its NanoKnife system to be used in prostate cancer ...

Canaccord Genuity analyst John Young CFA has maintained their bullish stance on ANGO stock, giving a Buy rating today.Pick the best stocks and ...

AngioDynamics (ANGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend ...

Shares of AngioDynamics hit a 52-week high after the company's NanoKnife System for prostate tissue ablation received regulatory clearance. The stock jumped almost 35% to a high of $9.42 in early ...

AngioDynamics (ANGO) announced it received U.S. FDA 510(k) clearance for the NanoKnife System for prostate tissue ablation. Pick the best ...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options ...

“We are incredibly proud to receive FDA clearance for the NanoKnife System’s use in prostate tissue,” said Jim Clemmer, President and Chief Executive Officer of AngioDynamics. “This ...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment ...